ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Corporation (Ambry), a leading clinical genetics-testing lab, recently published a paper concerning mutations in the FDXR gene, detailing how a team of researchers completed an entire diagnostic journey – from novel gene identification to potential treatment development; offering hope of a treatment to patients with vision loss due to mitochondrial disease. The paper, Biallelic mutations in the ferredoxin reductase gene cause novel mitochondr

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Corporation (Ambry), a leading clinical genetics-testing lab, recently published a paper concerning mutations in the FDXR gene, detailing how a team of researchers completed an entire diagnostic journey – from novel gene identification to potential treatment development; offering hope of a treatment to patients with vision loss due to mitochondrial disease. The paper, Biallelic mutations in the ferredoxin reductase gene cause novel mitochondr